Abstract 2360
Background
Extranodal marginal zone lymphoma is a type of low-grade B-cell lymphoma and may be classified as mucosal-associated lymphoid tissue (MALT) lymphoma. MALT lymphoma is most common in stomach in Korea. The etiologic factors are inflammation caused by chronic infection, autoimmune disease and genetic variation. Identifying various somatic mutations is an essential process in precision medicine, where high throughput sequencing is used to accurately detect genetic changes. Nucleotide sequencing techniques are basically based on the Sanger method, but recently second generation or next generation sequencing (NGS) that can sequence millions or billions of DNA strands simultaneously in parallel unlike the sanger sequencing is rapidly spreading.
Methods
One gastric MALT lymphoma and four small intestine MLAT lymphomas were selected and studied using tissue samples embedded in their paraffin. DNA was extracted from tissue samples and quality control was performed. NGS was performed using HemaSCANTM, a custom panel for 426 genes including essential genes for blood cancer.
Results
The results of NGS revealed the following genomic variants; single nucleotide variations (SNVs), insertions and deletions (InDels) and copy number variations (CNVs). And these genomic variants are reported as annotated, known, and novel variants. Of the annotated variant, ERBB2 gene amplification was confirmed in one patient. Of the known and novel variants, SNV of SETBP6, RUNX1 and KEAP1 gene, InDel of MKI67 gene, CNV of ZNF703 and NOTCH1 gene were confirmed in two or more patients. And InDel with frameshift in BCL10, DDX3X, FOXO3 and MUC2 genes was identified in one patient.
Conclusions
Since there are few NGS studies on MALT lymphoma, the various mutations identified in this study cannot be said to be “inactionable”. More studies are needed to determine the association of various genetic mutations with the development of MALT lymphoma.
Clinical trial identification
Editorial acknowledgement
Seok Jae Huh1, Sung Yong Oh1, Suee Lee1, Ji Hyun Lee1, Sung Hyun Kim1, Min Kyung Park2, and Hyo-Jin Kim1 1Department of Internal Medicine, Dong-A University Hospital, Busan, Republic of Korea, 2Department of Pathology, Dong-A University College of Medicine, Busan, Republic of Korea.
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
2432 - Retrospective comparative study of the efficacy and safety in docetaxel and ramucirumab combination chemotherapy with or without previous immune checkpoint inhibitor treatment.
Presenter: Daijiro Harada
Session: Poster Display session 1
Resources:
Abstract
2791 - Efficacy of weekly paclitaxel-bevacizumab combination in advanced non squamous non-small cell lung cancer (NSCLC) : a retrospective multicentric study.
Presenter: Geoffroy Bilger
Session: Poster Display session 1
Resources:
Abstract
2916 - Post progression survival for patients treated with docetaxel/nintedanib in the SENECA trial
Presenter: Enrica Capelletto
Session: Poster Display session 1
Resources:
Abstract
1427 - Final results of randomized phase II trial of metronomic vs weekly oral vinorelbine (OV) as first-line chemotherapy (CT) in advanced NSCLC patients unfit to platinum-based CT (P-CT): Tempo-Lung EudraCT Number: 2014-003859-61
Presenter: Dariusz Kowalski
Session: Poster Display session 1
Resources:
Abstract
3789 - Pioglitazone and clarithromycin combined with metronomic low-dose chemotherapy versus nivolumab in patients with advanced non–small-cell lung cancer treated in 2nd-line and beyond: Outcomes from a randomized phase II trial (ModuLung)
Presenter: Daniel Heudobler
Session: Poster Display session 1
Resources:
Abstract
1519 - Predicting Chemotherapy Toxicity in Elderly Patients with Advanced Non-small Cell Lung Cancer: A Prospective Multicenter Study of the National Hospital Organization in Japan
Presenter: Masaki Kanazu
Session: Poster Display session 1
Resources:
Abstract
1874 - A prospective phase II trial of carboplatin (CBDCA) and nab-paclitaxel (nabPTX) for advanced non-small cell lung cancer (NSCLC) with interstitial lung disease (ILD)
Presenter: Toshiyuki Harada
Session: Poster Display session 1
Resources:
Abstract
3819 - Weekly Epirubicin as palliative treatment in elderly patients with malignant pleural mesothelioma.
Presenter: Paola Candido
Session: Poster Display session 1
Resources:
Abstract
3390 - Survival Prolongation by Rationale INnovative Genomics (SPRING): An international WIN Consortium phase I study exploring safety and efficacy of avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer (NSCLC) with integrated genomic and transcriptomic correlates.
Presenter: Benjamin Solomon
Session: Poster Display session 1
Resources:
Abstract
5069 - Preliminary results from phase 1b study of spartalizumab plus chemotherapy for advanced non-small cell lung cancer (NSCLC)
Presenter: Armando Santoro
Session: Poster Display session 1
Resources:
Abstract